Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Cysteine-Independent Inhibition of Alzheimer's Disease-like Paired Helical Filament Assembly by Leuco-Methylthioninium (LMT).

Al-Hilaly YK, Pollack SJ, Rickard JE, Simpson M, Raulin AC, Baddeley T, Schellenberger P, Storey JMD, Harrington CR, Wischik CM, Serpell LC.

J Mol Biol. 2018 Oct 19;430(21):4119-4131. doi: 10.1016/j.jmb.2018.08.010. Epub 2018 Aug 16.

2.

The involvement of tau in nucleolar transcription and the stress response.

Maina MB, Bailey LJ, Wagih S, Biasetti L, Pollack SJ, Quinn JP, Thorpe JR, Doherty AJ, Serpell LC.

Acta Neuropathol Commun. 2018 Jul 31;6(1):70. doi: 10.1186/s40478-018-0565-6.

3.

Mental Health Service Utilization before and after Receipt of a Service-Connected Disability Award for PTSD: Findings from a National Sample.

Sripada RK, Hannemann CM, Schnurr PP, Marx BP, Pollack SJ, McCarthy JF.

Health Serv Res. 2018 Dec;53(6):4565-4583. doi: 10.1111/1475-6773.12859. Epub 2018 Apr 17.

PMID:
29667171
4.

Alzheimer's Disease-like Paired Helical Filament Assembly from Truncated Tau Protein Is Independent of Disulfide Crosslinking.

Al-Hilaly YK, Pollack SJ, Vadukul DM, Citossi F, Rickard JE, Simpson M, Storey JMD, Harrington CR, Wischik CM, Serpell LC.

J Mol Biol. 2017 Nov 24;429(23):3650-3665. doi: 10.1016/j.jmb.2017.09.007. Epub 2017 Sep 15.

5.

The involvement of dityrosine crosslinking in α-synuclein assembly and deposition in Lewy Bodies in Parkinson's disease.

Al-Hilaly YK, Biasetti L, Blakeman BJ, Pollack SJ, Zibaee S, Abdul-Sada A, Thorpe JR, Xue WF, Serpell LC.

Sci Rep. 2016 Dec 16;6:39171. doi: 10.1038/srep39171.

6.

Contrasting genetic architectures of schizophrenia and other complex diseases using fast variance-components analysis.

Loh PR, Bhatia G, Gusev A, Finucane HK, Bulik-Sullivan BK, Pollack SJ; Schizophrenia Working Group of Psychiatric Genomics Consortium, de Candia TR, Lee SH, Wray NR, Kendler KS, O'Donovan MC, Neale BM, Patterson N, Price AL.

Nat Genet. 2015 Dec;47(12):1385-92. doi: 10.1038/ng.3431. Epub 2015 Nov 2.

7.

Mental health outreach and screening among returning veterans: are we asking the right questions?

Bloeser K, McCarron KK, Batorsky B, Reinhard MJ, Pollack SJ, Amdur R.

US Army Med Dep J. 2014 Oct-Dec:109-17.

PMID:
25830806
8.

A comparative study of fragment screening methods on the p38α kinase: new methods, new insights.

Pollack SJ, Beyer KS, Lock C, Müller I, Sheppard D, Lipkin M, Hardick D, Blurton P, Leonard PM, Hubbard PA, Todd D, Richardson CM, Ahrens T, Baader M, Hafenbradl DO, Hilyard K, Bürli RW.

J Comput Aided Mol Des. 2011 Jul;25(7):677-87. doi: 10.1007/s10822-011-9454-9. Epub 2011 Jul 6.

9.

Integrative outpatient treatment for returning service members.

Batten SV, Pollack SJ.

J Clin Psychol. 2008 Aug;64(8):928-39. doi: 10.1002/jclp.20513.

PMID:
18561182
10.

Composition of perineuronal nets in the adult rat cerebellum and the cellular origin of their components.

Carulli D, Rhodes KE, Brown DJ, Bonnert TP, Pollack SJ, Oliver K, Strata P, Fawcett JW.

J Comp Neurol. 2006 Feb 1;494(4):559-77.

PMID:
16374793
11.

Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitors.

Fricker M, Lograsso P, Ellis S, Wilkie N, Hunt P, Pollack SJ.

Arch Biochem Biophys. 2005 Jun 15;438(2):195-205.

PMID:
15907786
12.

Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production.

Ryan EP, Pollock SJ, Murant TI, Bernstein SH, Felgar RE, Phipps RP.

J Immunol. 2005 Mar 1;174(5):2619-26. Erratum in: J Immunol. 2005 Apr;174(8):5134. Pollack, Stephen J [corrected to Pollock, Stephen J].

13.

Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.

Pollack SJ, Lewis H.

Curr Opin Investig Drugs. 2005 Jan;6(1):35-47. Review.

PMID:
15675602
14.

Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages.

Lewis HD, Pérez Revuelta BI, Nadin A, Neduvelil JG, Harrison T, Pollack SJ, Shearman MS.

Biochemistry. 2003 Jun 24;42(24):7580-6.

PMID:
12809514
15.

Small molecule Trk receptor agonists and other neurotrophic factor mimetics.

Pollack SJ, Harper SJ.

Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):59-80. Review.

PMID:
12769635
16.

Trk Neurotrophin Receptor Activators.

Pollack SJ, Harper SJ.

Drug News Perspect. 2002 Jun;15(5):268-277.

PMID:
12677222
17.

The non-peptidyl fungal metabolite L-783,281 activates TRK neurotrophin receptors.

Wilkie N, Wingrove PB, Bilsland JG, Young L, Harper SJ, Hefti F, Ellis S, Pollack SJ.

J Neurochem. 2001 Sep;78(5):1135-45.

18.

Sulphated compounds attenuate beta-amyloid toxicity by inhibiting its association with cells.

Sadler II, Smith DW, Shearman MS, Ragan CI, Tailor VJ, Pollack SJ.

Neuroreport. 1995 Dec 29;7(1):49-53.

PMID:
8742414
19.

The toxicity in vitro of beta-amyloid protein.

Iversen LL, Mortishire-Smith RJ, Pollack SJ, Shearman MS.

Biochem J. 1995 Oct 1;311 ( Pt 1):1-16. Review. No abstract available.

20.

Sulfonated dyes attenuate the toxic effects of beta-amyloid in a structure-specific fashion.

Pollack SJ, Sadler II, Hawtin SR, Tailor VJ, Shearman MS.

Neurosci Lett. 1995 Sep 15;197(3):211-4.

PMID:
8552301
21.

Inositol monophosphatase--a putative target for Li+ in the treatment of bipolar disorder.

Atack JR, Broughton HB, Pollack SJ.

Trends Neurosci. 1995 Aug;18(8):343-9. Review.

PMID:
7482796
22.

Structure and mechanism of inositol monophosphatase.

Atack JR, Broughton HB, Pollack SJ.

FEBS Lett. 1995 Mar 13;361(1):1-7. Review.

23.

Glycosaminoglycans and sulphated polyanions attenuate the neurotoxic effects of beta-amyloid.

Sadler II, Hawtin SR, Tailor V, Shearman MS, Pollack SJ.

Biochem Soc Trans. 1995 Feb;23(1):106S. No abstract available.

PMID:
7758665
24.

Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of beta-amyloid in rat PC12 cells.

Pollack SJ, Sadler II, Hawtin SR, Tailor VJ, Shearman MS.

Neurosci Lett. 1995 Jan 23;184(2):113-6.

PMID:
7724043
25.

Structural analysis of inositol monophosphatase complexes with substrates.

Bone R, Frank L, Springer JP, Pollack SJ, Osborne SA, Atack JR, Knowles MR, McAllister G, Ragan CI, Broughton HB, et al.

Biochemistry. 1994 Aug 16;33(32):9460-7.

PMID:
8068620
26.

Mechanism of inositol monophosphatase, the putative target of lithium therapy.

Pollack SJ, Atack JR, Knowles MR, McAllister G, Ragan CI, Baker R, Fletcher SR, Iversen LL, Broughton HB.

Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):5766-70.

27.

Probing the role of metal ions in the mechanism of inositol monophosphatase by site-directed mutagenesis.

Pollack SJ, Knowles MR, Atack JR, Broughton HB, Ragan CI, Osborne S, McAllister G.

Eur J Biochem. 1993 Oct 1;217(1):281-7.

28.

Cloning, overexpression and mechanistic studies of carboxyphosphonoenolpyruvate mutase from Streptomyces hygroscopicus.

Pollack SJ, Freeman S, Pompliano DL, Knowles JR.

Eur J Biochem. 1992 Oct 15;209(2):735-43.

29.

Design of catalytic antibodies.

Pollack SJ, Nakayama GR, Schultz PG.

Methods Enzymol. 1989;178:551-68. No abstract available.

PMID:
2601630
30.

Introduction of nucleophiles and spectroscopic probes into antibody combining sites.

Pollack SJ, Nakayama GR, Schultz PG.

Science. 1988 Nov 18;242(4881):1038-40.

PMID:
3194752
31.

Antibody catalysis by transition state stabilization.

Pollack SJ, Schultz PG.

Cold Spring Harb Symp Quant Biol. 1987;52:97-104. No abstract available.

PMID:
3454301
32.

Selective chemical catalysis by an antibody.

Pollack SJ, Jacobs JW, Schultz PG.

Science. 1986 Dec 19;234(4783):1570-3.

PMID:
3787262

Supplemental Content

Loading ...
Support Center